Bank of New York Mellon Corp increased its stake in bluebird bio, Inc. (NASDAQ:BLUE – Free Report) by 19.4% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 685,757 shares of the biotechnology company’s stock after buying an additional 111,574 shares during the quarter. Bank of New York Mellon Corp’s holdings in bluebird bio were worth $675,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in shares of bluebird bio by 19.6% in the first quarter. Vanguard Group Inc. now owns 10,498,460 shares of the biotechnology company’s stock worth $13,438,000 after buying an additional 1,723,081 shares in the last quarter. Ghisallo Capital Management LLC bought a new position in bluebird bio in the 4th quarter valued at approximately $4,347,000. Vestal Point Capital LP purchased a new stake in bluebird bio during the 4th quarter valued at $2,967,000. HBK Investments L P bought a new stake in shares of bluebird bio in the 4th quarter worth $2,070,000. Finally, Masters Capital Management LLC purchased a new position in shares of bluebird bio in the fourth quarter worth $1,380,000. Hedge funds and other institutional investors own 87.43% of the company’s stock.
bluebird bio Stock Down 4.4 %
NASDAQ BLUE opened at $0.47 on Monday. bluebird bio, Inc. has a 52 week low of $0.46 and a 52 week high of $5.53. The company has a 50 day moving average price of $0.83 and a 200 day moving average price of $0.99. The firm has a market cap of $51.41 million, a PE ratio of -0.64 and a beta of 0.75.
Analyst Ratings Changes
Get Our Latest Analysis on BLUE
bluebird bio Profile
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.
Further Reading
- Five stocks we like better than bluebird bio
- ETF Screener: Uses and Step-by-Step Guide
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- What Are the FAANG Stocks and Are They Good Investments?
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Low PE Growth Stocks: Unlocking Investment Opportunities
- MarketBeat Week in Review – 9/16 – 9/20
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUE – Free Report).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.